search:v2 receptor antagonist相關網頁資料

- www.ncbi.nlm.nih.gov
  
  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
  
  1. N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. ...
  
  2024-07-21
  
  瀏覽：433
- www.nejm.org
  
  Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia — NEJM
  
  Original Article from The New England Journal of Medicine — Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia ... Results Serum sodium concentrations increased more in the tolvaptan group than in the placebo group during the
  
  2024-07-18
  
  瀏覽：305

v2 receptor antagonist的相關文章

v2 receptor antagonist的相關公司資訊

v2 receptor antagonist的相關商品

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and

日期：2024-07-17

1. Prog Brain Res. 2002;139:197-210. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G. The involvem...

全文

Vasopressin receptor antagonist - Wikipedia, the free encyclopedia

日期：2024-07-19

A vasopressin receptor antagonist (VRA) is an agent which interferes with action at the vasopressin receptors. Most commonly VRAs are used in the treatment of hyponatremia, especially in patients with congestive heart failure, liver cirrhosis or SIADH.[1]...

全文

1. Vasopressin V2 receptor - DrugBank

日期：2024-07-19

References: Hiroyama M, Wang S, Aoyagi T, Oikawa R, Sanbe A, Takeo S, Tanoue A: Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice. Eur J Pharmacol. 2007 Mar 22;559(2-3):89-97. Epub 2006 Dec 29. Pubmed ......

全文

Tolvaptan, a Selective Oral Vasopressin V -Receptor Antagonist, for Hyponatremia

日期：2024-07-20

Tolvaptan for Hyponatremia n engl j med 355;20 www.nejm.org november 16, 2006 2103 244 Patients underwent screening 205 Met inclusion criteria 102 Assigned to tolvaptan 15 mg daily 103 Assigned to placebo 15 mg daily Increased to 30 mg or 60 mg, if ......

全文

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor An

日期：2024-07-21

Title Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V 2-Receptor Antagonist Tolvaptan Journal Digestive Diseases and Sciences Volume 57, Issue 11 , pp 2774-2785 Cover Date 2012-11-01 DOI 10.1007/s10620-012-2276-3...

全文

SAMSCA® (tolvaptan) Mechanism of Action

日期：2024-07-19

References: Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-S4. Knoers NVAM. Hyperactive vasopressin receptors and disturbed water ......

全文

Vasopressin V2 receptor antagonists | Cardiovascular Research

日期：2024-07-19

15 Aug 2001 ... Activation of the vasopressin V2 receptor, mainly present in renal collecting ducts , leads to an increase in intracellular cAMP by stimulating ......

全文

Neuropsychopharmacology - Effects of Buprenorphine Maintenance Dose on [mu]-Opioid Receptor Availabi

日期：2024-07-17

Top of page INTRODUCTION Buprenorphine (BUP) is a high-affinity, -opioid receptor (OR) partial agonist and -opioid antagonist (Cowan et al, 1977; Heel et al, 1979; Lewis et al, 1983). BUP's OR actions offer agonist substitution (thereby reducing drug use,...

全文

12 > »